Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis release_uvgldl4xdvdxhmhcqj62l2igyi

by Min Seo Kim, Min Ho An, Won Jun Kim, Tae-Ho Hwang

References

This release citing other releases
  1. Network meta-analysis: a norm for comparative effectiveness? The Lancet.2015628 (DOI: 10.1016/s0140-6736(15)61478-7)
  2. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med.2015777 (DOI: 10.7326/m14-2385)
  3. Comparative Efficacy and Safety of Pharmacological Managements for Hospitalized COVID-19 Patients: Protocol for Systematic Review and Trade-Off Network Meta-Analysis. medRxiv..2020
  4. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis The Lancet.2019939 (DOI: 10.1016/s0140-6736(19)31135-3)
  5. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis The Lancet.2019768 (DOI: 10.1016/s0140-6736(18)31793-8)
  6. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials BMJ.2010c4737 (DOI: 10.1136/bmj.c4737)
  7. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis The Lancet.2017747 (DOI: 10.1016/s0140-6736(17)31441-1)
  8. Organised inpatient (stroke unit) care for stroke: network meta-analysis. Cochrane Database Syst Rev.2020
  9. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal BMJ.2020
  10. The impact of 2019 novel coronavirus on heart injury: A systemic review and Meta-analysis. Prog Cardiovasc Dis..2020518 (DOI: 10.1016/j.pcad.2020.04.008)
  11. AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 Gastroenterology.2020320 (DOI: 10.1053/j.gastro.2020.05.001)
  12. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. The Lancet Child & Adolescent Health..2020397 (DOI: 10.1016/s2352-4642(20)30095-x)
  13. Combining randomized and non-randomized evidence in network meta-analysis. Stat Med.20171210 (DOI: 10.1002/sim.7223)
  14. Efficacy and safety of pharmacological treatments for Patent Ductus Arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies Pharmacol Res.2019104418 (DOI: 10.1016/j.phrs.2019.104418)
  15. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis BMJ.2018k4029 (DOI: 10.1136/bmj.k4029)
  16. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med.2018642 (DOI: 10.1136/bjsports-2017-098043)
  17. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. PLoS Med..2020e1003130 (DOI: 10.1371/journal.pmed.1003130)
  18. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study BMJ.2020
  19. Multisystem inflammatory syndrome in US children and adolescents N Engl J Med.2020334 (DOI: 10.1056/nejmoa2021680)
  20. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Hospital Research Institute.2012
  21. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials.1999448 (DOI: 10.1016/s0197-2456(99)00026-4)
  22. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions BMJ.2016i4919 (DOI: 10.1136/bmj.i4919)
  23. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis BMJ.2014g5630 (DOI: 10.1136/bmj.g5630)
  24. Graphical tools for network meta-analysis in STATA. Plos ONE.2013e76654 (DOI: 10.1371/journal.pone.0076654)
  25. Software and package applicating for network meta-analysis: A usage-based comparative study. J Evid Based Med.2018176 (DOI: 10.1111/jebm.12264)
  26. Network meta-analysis: application and practice using Stata. Epidemiol Health..2017 (DOI: 10.4178/epih.e2017047)
  27. Network meta-analysis using R: a review of currently available automated packages. Plos ONE..2014e115065 (DOI: 10.1371/journal.pone.0115065)
  28. Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis J Psychiatr Res.2020164 (DOI: 10.1016/j.jpsychires.2020.03.012)
  29. Comparative Efficacy and Tolerability of Nonsurgical Therapies for the Treatment of Midportion Achilles Tendinopathy: A Systematic Review With Network Meta-analysis. Orthop J Sports Med..20202325967120930567
  30. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol..200513 (DOI: 10.1186/1471-2288-5-13)
  31. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol.2014135 (DOI: 10.1186/1471-2288-14-135)
  32. Network meta-analysis for indirect treatment comparisons. Stat Med..20022313 (DOI: 10.1002/sim.1201)
  33. Quantifying heterogeneity in a meta-analysis. Stat Med.20021539 (DOI: 10.1002/sim.1186)
  34. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol.201335 (DOI: 10.1186/1471-2288-13-35)
  35. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol.201558 (DOI: 10.1186/s12874-015-0060-8)
  36. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis The Lancet HIV.2017e433 (DOI: 10.1016/s2352-3018(17)30109-1)
  37. Comparison of sputum collection methods for tuberculosis diagnosis: a systematic review and pairwise and network meta-analysis Lancet Glob Health.2017e760 (DOI: 10.1016/s2214-109x(17)30201-2)
  38. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev..2015147 (DOI: 10.1186/s13643-015-0133-0)
  39. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 Nature.2020
  40. Dexamethasone inhibits inflammation and cartilage damage in a new model of post-traumatic osteoarthritis J Orthop Res.2014566 (DOI: 10.1002/jor.22568)
  41. The role of the glucocorticoid receptor in inflammation and immunity J Steroid Biochem Mol Biol.201069 (DOI: 10.1016/j.jsbmb.2010.03.058)
  42. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs N Engl J Med.20051711 (DOI: 10.1056/nejmra050541)
  43. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review J Rheumatol.201110 (DOI: 10.3899/jrheum.100717)
  44. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet.2008987 (DOI: 10.1016/s0140-6736(08)60453-5)
  45. Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation Cell Transplant.20141199 (DOI: 10.3727/096368913x667529)
  46. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series Arthritis Rheum.2011545 (DOI: 10.1002/art.30128)
  47. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial The Lancet.2008998 (DOI: 10.1016/s0140-6736(08)60454-7)
  48. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev..2003
  49. Cochrane Review: Intravenous immunoglobulin for Guillain-Barré syndrome. Evidence-Based Child Health: A Cochrane Review Journal..20111176 (DOI: 10.1002/ebch.810)
  50. Anti-inflammatory actions of intravenous immunoglobulin Annu Rev Immunol.2008513 (DOI: 10.1146/annurev.immunol.26.021607.090232)
  51. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock Cochrane Database Syst Rev.2013
  52. A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections. medRxiv..2020
  53. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clin Infect Dis.2020
  54. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ.2020
  55. COVID-19: consider cytokine storm syndromes and immunosuppression Lancet (London, England)..20201033 (DOI: 10.1016/s0140-6736(20)30628-0)
  56. COVID-19: immunopathology and its implications for therapy Nat Rev Immunol.2020269 (DOI: 10.1038/s41577-020-0308-3)
  57. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv..2020
  58. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect..2020e11 (DOI: 10.1016/j.jinf.2020.07.008)
  59. Long-term side effects of glucocorticoids. Expert Opin Drug Saf.2016457 (DOI: 10.1517/14740338.2016.1140743)
  60. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis.2020ciaa1177
  61. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv..2020
  62. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019. Eur Rev Med Pharmacol Sci.20208194
  63. Dexamethasone in hospitalized patients with Covid-19—preliminary report N Engl J Med.2020
  64. Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study BMJ.2018k585 (DOI: 10.1136/bmj.k585)
  65. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State JAMA.2020
  66. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol..20201036 (DOI: 10.1001/jamacardio.2020.1834)
  67. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc.2020e017144 (DOI: 10.1161/jaha.120.017144)
  68. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circulation: Arrhythmia and Electrophysiology..
  69. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol..20201067 (DOI: 10.1001/jamacardio.2020.1787)
  70. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open.2020e208857 (DOI: 10.1001/jamanetworkopen.2020.8857)
  71. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv.2020
  72. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data BMJ.2020
  73. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ.2020m1849 (DOI: 10.1136/bmj.m1849)
  74. Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea. medRxiv..2020
  75. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 N Engl J Med.2020
  76. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial Ann Intern Med.2020623 (DOI: 10.7326/m20-4207)
  77. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial Clin Infect Dis.2020
  78. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 N Engl J Med.2020
  79. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease. medRxiv..2020
  80. Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv..2020